SciFest Welcomes Mallinckrodt Pharmaceuticals as a New Project Partner
SciFest, Ireland’s largest science, technology, engineering, and math (‘STEM’) fair programme for second-level schools, is delighted to announce that Mallinckrodt Pharmaceuticals (‘Mallinckrodt’) has joined the programme as a Project Partner, alongside Intel Ireland, Boston Scientific and EirGrid. Mallinckrodt, a global specialty pharmaceutical company, develops medicines and therapies that address unmet patient needs and improve outcomes for patients with severe and critical conditions.
Mallinckrodt has a proud history of operations in Ireland for over 30 years. As the company’s corporate headquarters, the Blanchardstown, Dublin 15 facility also has responsibility for global functions including manufacturing, global device engineering and innovative research and development. Mallinckrodt’s commitment to improving patient outcomes through science, innovation and R&D, makes them an ideal fit for supporting SciFest’s mission to inspire and nurture young STEM talent in Ireland.
With Mallinckrodt’s support, SciFest is expanding its reach and impact, providing more opportunities for second-level students across the country to showcase their STEM projects and to engage with professionals from diverse scientific and technical fields.
Each year, qualifying winners from the 16 regional SciFest STEM fairs are invited to compete in the SciFest National Final. Awards at the National Final include the opportunity to represent Ireland at international competitions and events in the United States and Germany. The 2024 National Final will take place on Thursday and Friday, 28 and 29 November, at Marino Institute of Education, Griffith Avenue, Dublin 9.
Paul O’Neill, Executive Vice President, Quality & Operations, Mallinckrodt, commented: “As an innovation-driven specialty pharmaceutical company, we are delighted to partner with SciFest to promote STEM disciplines across second-level education in Ireland. We are excited to meet students and share our knowledge and experience. Our ambition is to inspire young students to pursue future careers in STEM and to see the opportunity before them, equipped with these disciplines, to enhance human health and improve the lives of patients all over the world.”
Sheila Porter, SciFest Founder and CEO, speaking about the new partnership said: "We are delighted to welcome Mallinckrodt Pharmaceuticals to the SciFest community. Their commitment to advancing medical science through innovation aligns perfectly with SciFest’s goals of fostering curiosity, creativity, and critical thinking in young minds. With their support, we can continue to inspire the next generation of scientists and innovators, helping them to realize their full potential."
About SciFest
SciFest is a series of one-day science fairs hosted locally in schools and regional venues across Ireland. It provides students with an inclusive and accessible platform to present their STEM projects and develop essential skills for their future careers.
For more information about the SciFest programme, please visit www.scifest.ie.
About Mallinckrodt
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients.
To learn more about Mallinckrodt, please visit www.mallinckrodt.com.